Ownership history in GENERAL ATLANTIC, L.P. · 10 quarters on record
This page tracks every 13F SEC filing in which GENERAL ATLANTIC, L.P. reported a position in AKERO THERAPEUTICS (AKRO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | UNCHANGED | 5,733,989 | — | 0% | 8.17% | $272.2M | — |
| 2025 Q2 | ADDED | 5,733,989 | +500,000 | +9.6% | 8.43% | $306.0M | — |
| 2025 Q1 | UNCHANGED | 5,233,989 | — | 0% | 7.11% | $211.9M | — |
| 2024 Q4 | UNCHANGED | 5,233,989 | — | 0% | 5.18% | $145.6M | — |
| 2024 Q3 | UNCHANGED | 5,233,989 | — | 0% | 4.27% | $150.2M | — |
| 2024 Q2 | UNCHANGED | 5,233,989 | — | 0% | 3.86% | $122.8M | — |
| 2024 Q1 | ADDED | 5,233,989 | +3,448,275 | +193.1% | 3.07% | $132.2M | — |
| 2023 Q4 | UNCHANGED | 1,785,714 | — | 0% | 0.60% | $41.7M | — |
| 2023 Q3 | UNCHANGED | 1,785,714 | — | 0% | 1.39% | $90.3M | — |
| 2023 Q2 | INITIATED | 1,785,714 | — | — | 1.31% | $83.4M | — |